KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $6.02 $13.63 Friday, 26th Apr 2024 VERV stock ended at $6.16. This is 0.96% less than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.47% from a day low at $6.02 to a day high of $6.41.
90 days $6.02 $19.34
52 weeks $6.02 $21.42

Historical Verve Therapeutics, Inc. prices

Date Open High Low Close Volume
Feb 14, 2024 $12.60 $12.80 $12.04 $12.75 1 136 995
Feb 13, 2024 $12.35 $12.73 $12.01 $12.19 1 190 349
Feb 12, 2024 $12.45 $13.59 $12.40 $13.43 1 712 585
Feb 09, 2024 $12.04 $12.62 $11.91 $12.40 1 107 775
Feb 08, 2024 $10.95 $11.87 $10.79 $11.81 1 288 301
Feb 07, 2024 $11.44 $11.45 $10.78 $10.95 1 176 712
Feb 06, 2024 $10.76 $11.48 $10.65 $11.46 1 012 693
Feb 05, 2024 $10.78 $10.83 $10.31 $10.81 1 220 928
Feb 02, 2024 $10.89 $11.14 $10.48 $11.01 846 738
Feb 01, 2024 $10.84 $11.38 $10.67 $11.21 964 345
Jan 31, 2024 $11.21 $11.59 $10.77 $10.82 1 087 233
Jan 30, 2024 $11.90 $11.91 $11.18 $11.25 800 496
Jan 29, 2024 $11.60 $12.12 $11.32 $11.99 1 045 623
Jan 26, 2024 $12.05 $12.37 $11.46 $11.54 713 173
Jan 25, 2024 $11.67 $12.25 $11.50 $11.85 993 340
Jan 24, 2024 $12.32 $12.49 $11.45 $11.46 741 704
Jan 23, 2024 $12.73 $13.09 $11.87 $12.17 696 041
Jan 22, 2024 $12.02 $12.65 $12.00 $12.39 987 491
Jan 19, 2024 $12.32 $12.32 $11.83 $11.94 691 498
Jan 18, 2024 $12.57 $12.57 $11.81 $12.32 878 115
Jan 17, 2024 $12.12 $12.43 $11.89 $12.38 1 096 400
Jan 16, 2024 $12.50 $12.69 $11.90 $12.54 933 386
Jan 12, 2024 $13.11 $13.47 $12.71 $12.77 754 473
Jan 11, 2024 $13.50 $13.59 $12.77 $13.01 1 385 316
Jan 10, 2024 $13.89 $14.16 $13.30 $13.79 795 996
Click to get the best stock tips daily for free!

About Verve Therapeutics, Inc.

Verve Therapeutics. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with... VERV Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT